Increased focus on post-market safety and value has resulted in CROs handling more Phase IV work, according to a PharmaNet EVP, and this trend may continue as regulators seek real world evidence.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
